RetaMaps

BEAUTIQUE by Dr. Mel | Medical Spa

BEAUTIQUE by Dr. Mel | Medical Spa · 1348 Saint Georges Avenue · Woodbridge Township, NJ 07001

4.8· 42 Google reviews

Listing updated October 2, 2026

Retatrutide outlook for this practice

No current plans confirmed — RetaMaps has not yet confirmed this practice's intentions regarding retatrutide. Inclusion on RetaMaps does not mean the provider offers or will offer retatrutide.

Care described on the practice's website

  • Medically supervised weight loss

About this practice

BEAUTIQUE by Dr. Mel is a medical spa in Woodbridge Township, New Jersey, whose website describes non-surgical aesthetic treatments including dermal fillers, injectables, laser hair removal and hair rejuvenation, performed by medical professionals, along with Hydrafacial skin treatments and free consultations. Its site says the physician behind the practice is board certified in both Internal Medicine and Obesity Medicine, and the listing includes weight-loss care. Google shows a 4.8-star rating across 42 reviews dating to 2023, with 3 in the past year. Reviewers most often mention the team's knowledge and the staff.

Services & access

Advertises semaglutide todayNot listed
Advertises tirzepatide todayNot listed
Telehealth visitsNot listed
Cash pay accepted—
Accepts insurance — per practice websiteYes
Accepting new patients — per practice websiteYes

"Not listed" means we didn't find this stated on the practice's public pages — it doesn't mean no. — means unknown. Medication rows describe currently FDA-approved GLP-1 medications the practice advertises today, not retatrutide. Confirm details directly with the practice.

Review activity

★ 4.8
Google rating · 42 reviews
3
reviews in the past year (avg ★ 5.0)

Counts computed by RetaMaps from public Google reviews; most recent review 2026-06-25. Read the reviews themselves on the practice's Google listing.

What patients say

Rated ★4.8 across 42 Google reviews. Of the 39 reviews we analyzed, 37 (95%) are positive (4–5★) and 2 (5%) are negative (1–2★).

What patients like

  • Friendly, helpful staff7 reviews
  • Knowledgeable, professional providers6 reviews
  • Feeling listened to3 reviews
  • Weight-loss results2 reviews

Common complaints

Very few complaints — only 2 negative reviews, with no recurring theme.

5★
37
4★
0
3★
0
2★
0
1★
2

Most recent Google reviews

MR★★★★★2026-06-25

Fillers and Botox Looks very rejuvenating and natural I don’t want to look superficial and Dr. Mel accomplishes that for me.

Dawn C.★★★★★2026-02-19

Dr. Mel is wonderful! I highly recommend her!

Bhargav P.★★★★★2025-09-24

Melvina was very good. Highly recommended

S K.★★★★★2025-09-11

Had a great experience with Dr Mel. She is very friendly and explains everything in details. This was my first time ever getting a skin treatment done. Dr Mel takes her time with you and makes her recommendations. She doesn’t push you to get any additional services/treatments done if not needed.

Steven D.★★★★★2025-07-07

DR. Mel explained everything clearly and was very informative. I Definity recommend her.

Analysis by RetaMaps of reviews on this practice's public Google Business listing; review themes are detected automatically and reviews reflect their authors' opinions. See all reviews on Google.

Nearby providers in Woodbridge Township

Nexa Vitality

33 South Wood Avenue · Woodbridge Township, NJ 08830

4.5(20 Google reviews · 1 in past year)

TelehealthAccepts insuranceSemaglutide todayTirzepatide today4 reviews mention GLP-1
View profileVisit website
Listing updated Oct 2, 2026
Retatrutide status
Phase 3 complete · Not FDA-approvedUpdated October 2, 2026

Retatrutide is Eli Lilly's investigational once-weekly triple agonist (GIP, GLP-1 and glucagon receptors). Five Phase 3 trials have reported positive results, and Lilly plans to submit it to the FDA in Q1 2027. It is not FDA-approved, has no brand name or price, and cannot be prescribed outside clinical trials or Lilly's physician-requested expanded access program. Products sold online as "research" or compounded retatrutide are not legitimate retatrutide.

Development
Phase 3 complete
FDA status
Submission planned — Q1 2027 (Lilly guidance)
Availability
Not commercially available
Access routes
Clinical trials, or Lilly's expanded access program (physician must apply)

Next milestone: TRIUMPH-5 head-to-head vs tirzepatide results (Expected ~Dec 2026)

Sources: Lilly — What to know about retatrutide · Lilly — TRIUMPH-2/TRIUMPH-3 results · BioPharma Dive — FDA submission plans · STAT — Lilly expanded access (Aug 3, 2026) · FDA — Concerns with unapproved GLP-1 drugs